-
New day-trip ferry service starts from France to Jersey
Travellers can spend up to five hours on island before returning to mainland
-
Tour de France 2025: will the route pass near you next week?
Both the men’s and women’s races will be held entirely in France this year
-
Photos: have you visited Saint-Antoine-l'Abbaye, France’s favourite village 2025?
This year’s village préféré des Français is home to a 1095 Gothic Abbey
‘Real risk’ of second wave of Covid-19
The risk of a second wave of Covid-19 from the end of October is real, the head of France’s scientific advisory council has warned.

A second wave
“It could start off again in France, or elsewhere,” Professor Jean-François Delfraissy told an inquiry into the handling of Covid-19. “That’s why we have to be very attentive to barrier measures, because for now there’s no really effective treatment and no vaccine.” He said, however, that a new general confinement would be “impossible and undesirable for economic and social reasons”.
New Covid-19 clusters
A total of 216 new Covid-19 clusters were reported in mainland France in the latest figures available (June 16) since the end of lockdown. Health authorities say cases are mainly under control but issued a warning to remain vigilant. Thirty cases were in Sarcelles (Val-d’Oise). Professor Didier Raoult, the infectious diseases expert who championed anti-viral drugs hydroxychloroquine and chloroquine to treat coronavirus, has also warned of a possible new wave. He said we should watch New Zealand as it has similar conditions to France and is entering its winter season.
France deconfinement: What opens June 22, in July and beyond
Treatment trials
France has been considering whether to resume trials of the use of hydroxychloroquine against Covid-19 as part of the European Discovery tests after doubt was cast on the reliability of a study in British journal The Lancet, which said it caused increased deaths. The article influenced France to ban it as a treatment. The WHO removed the drug from its Solidarity trial, saying it did not reduce mortality, based on its own results and the UK’s Recovery trial.